Molecular characterization of hepatocarcinogenesis using mouse models.

Area of Science:

• Hepatology
• Oncology
• Translational Medicine

Background:

• Hepatocellular carcinoma (HCC) is a significant global health challenge, often diagnosed late with limited treatment options.
• Early detection biomarkers and therapeutic targets are crucial for improving HCC patient outcomes.
• Understanding the sequential molecular changes during HCC development is essential for identifying early intervention strategies.

Purpose of the Study:

• To utilize mouse models to systematically study molecular pathways deregulated during HCC formation.
• To identify early biomarkers and potential therapeutic targets for hepatocellular carcinoma.
• To investigate the synergistic effects of etiological factors and gender bias in HCC development.

Main Methods:

• Hepatitis B surface antigen transgenic mice were exposed to aflatoxin B1 to model HCC.
• Longitudinal analysis of molecular pathways and gene expression changes during tumor development.
• Histological and molecular characterization of tumors to compare with human HCC.
• Identification of an 11-gene HCC-expression signature.

Main Results:

• A synergistic effect between hepatitis B and aflatoxin B1 was observed, with male mice showing higher HCC predisposition.
• Non-quiescent liver was necessary for effective transformation by aflatoxin B1.
• Mouse model tumors exhibited histological and molecular similarities to human HCC.
• An 11-gene signature distinguished HCC cells from normal hepatocytes and other cancers.
• Distinct and common molecular pathways were identified across different etiologies leading to HCC.

Conclusions:

• Mouse models are valuable for longitudinal studies of HCC molecular progression and biomarker discovery.
• The identified 11-gene signature holds potential for early HCC detection.
• Understanding etiology-specific and common molecular perturbations can guide targeted therapeutic strategies for HCC.
• Further research using these models can accelerate the development of novel HCC therapies.